Your browser doesn't support javascript.
loading
Correction to: LNC942 promoting METTL14-mediated m 6 A methylation in breast cancer cell proliferation and progression.
Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Li, Yalun; Wang, Yuanhe; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe.
Afiliación
  • Sun T; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, PR China.
  • Wu Z; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, PR China.
  • Wang X; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, 110122, PR China.
  • Wang Y; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, PR China.
  • Hu X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, PR China.
  • Qin W; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, PR China.
  • Lu S; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, 110122, PR China.
  • Xu D; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, PR China.
  • Wu Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, PR China.
  • Chen Q; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, PR China.
  • Ding X; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, 110122, PR China.
  • Guo H; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, PR China.
  • Li Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, PR China.
  • Wang Y; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, PR China.
  • Fu B; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, 110122, PR China.
  • Yao W; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, PR China.
  • Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, PR China.
  • Wu H; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, PR China.
Oncogene ; 41(11): 1677, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35169255
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article